9 Global Options Stem Cell Therapy for Parkinson #39;s Disease
Parkinson #39;s disease is a neuromuscular condition that affects millions of people around the world. Uncontrollable movement of the body muscles along with strong shaking and trembling of extremiti...
By: placidways
See original here:
9 Global Options Stem Cell Therapy for Parkinson's Disease - Video
Kickstarter Promo Update Sept 15 2014 - Stem Cell Treatment for Hope, Love and Freedom
Hello my name is Sonny, I was born with a nerve disease, a genetic mutation that causes the muscles in my arms, hands, legs and feet to atrophy and to become weak. I now have perfect legs....for...
By: Sonny Davis
Read the rest here:
Kickstarter Promo Update Sept 15 2014 - Stem Cell Treatment for Hope, Love and Freedom - Video
Medical Guidelines for Stem Cell Therapy in Australia
Dr Ralph Bright of Macquarie Stem Cells discusses the medical guidelines for practicing Stem Cell Therapy in Australia. http://www.macquariestemcells.com/ https://www.facebook.com/macquariestemcel...
By: Macquarie Stem Cells
Read the original here:
Medical Guidelines for Stem Cell Therapy in Australia - Video
History of Stem Cells
Dr Ralph Bright discusses the origins of his interest in Stem Cell therapy and how he discovered their power to heal conditions like Osteoarthritis.
By: Macquarie Stem Cells
See the article here:
Stem Cell Therapy | why no more news about embryonic stem cells
http://www.arthritistreatmentcenter.com Is embryonic stem cell research passe? Next How come no more news about embryonic stem cells? Embryonic stem cells co...
By: Nathan Wei
Link:
Stem Cell Therapy | why no more news about embryonic stem cells - Video
PUBLIC RELEASE DATE:
18-Sep-2014
Contact: Louise Walsh louise.walsh@admin.cam.ac.uk 44-012-237-65443 University of Cambridge @Cambridge_Uni
Stem cells hold great promise as a means of repairing cells in conditions such as multiple sclerosis, stroke or injuries of the spinal cord because they have the ability to develop into almost any cell type. Now, new research shows that stem cell therapy can also work through a mechanism other than cell replacement.
In a study published today in Molecular Cell, a team of researchers led by the University of Cambridge has shown that stem cells "communicate" with cells by transferring molecules via fluid filled bags called vesicles, helping other cells to modify the damaging immune response around them.
Although scientists have speculated that stem cells might act rather like drugs in sensing signals, moving to specific areas of the body and executing complex reactions this is the first time that a molecular mechanism for this process has been demonstrated. By understanding this process better, researchers can identify ways of maximising the efficiency of stem-cell-based therapies.
Dr Stefano Pluchino from the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, who led the study, said: "These tiny vesicles in stem cells contain molecules like proteins and nucleic acids that stimulate the target cells and help them to survive they act like mini "first aid kits".
"Essentially, they mirror how the stem cells respond to an inflammatory environment like that seen during complex neural injuries and diseases, and they pass this ability on to the target cells. We think this helps injured brain cells to repair themselves."
Mice with damage to brain cells such as the damage seen in multiple sclerosis show a remarkable level of recovery when neural stem/precursor cells (NPCs) are injected into their circulatory system. It has been suggested that this happens because the NPCs discharge molecules that regulate the immune system and that ultimately reduce tissue damage or enhance tissue repair.
The team of researchers from the UK, Australia, Italy, China and Spain has now shown that NPCs make vesicles when they are in the vicinity of an immune response, and especially in response to a small protein, or cytokine, called Interferon-gamma which is released by immune cells. This protein has the ability to regulate both the immune responses and intrinsic brain repair programmes and can alter the function of cells by regulating the activity of scores of genes.
See more here:
Edgar Irastorza was just 31 when his heart stopped beating in October 2008.
A Miami property manager, Irastorza had recently gained weight as his wife's third pregnancy progressed. "I kind of got pregnant, too," he said.
During a workout one day, he felt short of breath and insisted that friends rush him to the hospital. Minutes later, his pulse flatlined. He survived the heart attack, but the scar tissue that resulted cut his heart's pumping ability by a third. He couldn't pick up his children. He fell asleep every night wondering if he would wake up in the morning.
Desperation motivated Irastorza to volunteer for a highly unusual medical research trial: getting stem cells injected directly into his heart. "I just trusted my doctors and the science behind it, and said, 'This is my only chance,' " he said recently.
Over the last five years, by studying stem cells in lab dishes, test animals and intrepid patients like Irastorza, researchers have brought the vague, grandiose promises of stem cell therapies closer to reality.
Stem cells broke into the public consciousness in the early 1990s, alluring for their potential to help the body beat back diseases of degeneration like Alzheimer's, and to grow new parts to treat conditions like spinal cord injuries.
Progress has been slow. But researchers are learning how to best use stem cells, what types to use and how to deliver them to the body findings that are not singularly transformational, but progressive and pragmatic.
As many as 4,500 clinical trials involving stem cells are under way in the United States to treat patients with heart disease, blindness, Parkinson's, HIV, blood cancers and spinal cord injuries, among other conditions.
Initial studies suggest that stem cell therapy can be delivered safely, said Dr. Ellen Feigal, senior vice president of research and development at the California Institute of Regenerative Medicine, the state stem cell agency, which has awarded more than $2 billion toward stem cell research since 2006.
But enthusiasm for stem cells sometimes outstrips the science. When Gov. Rick Perry of Texas had adult stem cells injected into his spine in 2011 for a back injury, his surgeon had never tried the procedure and had no data to support the experiment. A June review in the New England Journal of Medicine found that "platelet-rich plasma" stem cell therapies praised by a number of athletes worked no better than placebos.
Read the original:
Investigators from the Institute for Research in Immunology and Cancer (IRIC) at the Universit de Montral have just published, in the journal Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord stem cells are used for transplants aimed at curing a number of blood-related diseases, including leukemia, myeloma and lymphoma. For many patients this therapy comprises a treatment of last resort.
Directed by Dr. Guy Sauvageau, principal investigator at IRIC and hematologist at the Maisonneuve-Rosemont Hospital, the research has the potential to multiply by 10 the number of cord blood units available for a transplant in humans. In addition, it will considerably reduce the complications associated with stem cell transplantation. And it will be particularly useful for non-Caucasian patients for whom compatible donors are difficult to identify.
A clinical study using this molecule, named UM171 in honor of the Universit de Montral, and a new type of bioreactor developed for stem culture in collaboration with the University of Toronto will be initiated in December 2014 at the Maisonneuve-Rosemont Hospital.
According to Dr. Guy Sauvageau, "This new molecule, combined with the new bioreactor technology, will allow thousands of patients around the world access to a safer stem cell transplant. Considering that many patients currently cannot benefit from a stem cell transplant for lack of matching donors, this discovery looks to be highly promising for the treatment of various types of cancer."
The Centre of Excellence for Cellular Therapy at the Maisonneuve-Rosemont Hospital will serve as production unit for these stem cells, and grafts will then be distributed to patients in Montreal, Quebec City and Vancouver for this first Canadian clinical study. Tangible results should be available one year later, that is, in December 2015. The significance of this new discovery is such that over time, conclusive clinical results could revolutionize the treatment of leukemia and other blood-related illnesses.
"These extraordinary advances result from the efforts of a remarkable team that includes extremely gifted students and postdoctoral investigators working in the IRIC laboratories," adds Dr. Guy Sauvageau. "Among them, the first authors of this publication: Iman Fars, doctoral student, and Jalila Chagraoui, research officer, along with the professionals in IRIC's medical chemistry core facility under the direction of Anne Marinier, who optimized the therapeutic properties of this new molecule."
Context
Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants, since their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune reaction in the recipient.
Furthermore, it is not necessary for the immunological compatibility between donor and recipient to be perfect, unlike in a bone marrow transplant. However, in most cases the number of stem cells obtained from an umbilical cord is much too low for treating an adult, and its use is confined above all to the treatment of children. With the new molecule UM171 it will be possible to multiply stem cells in culture and to produce enough of them to treat adults, especially those who are not Caucasian, and who because of the lack of donors have limited access to transplants.
Collaborators from the Maisonneuve-Rosemont Hospital, the British Columbia Cancer Agency, the Ontario Cancer Institute and the Fred Hutchison Cancer Research Center also played an important role in evaluating the biological properties of this new molecule, and those from the University of Toronto in developing the bioreactor.
The rest is here:
New molecule allows for up to 10-fold increase in stem cell transplants
ABC Ralph Bright harvests stem cells using the liposuction.
Serious questions have been raised about a stem cell doctor working in Western Sydney who charges $9,000 per procedure and uses methods that are untested by clinical trials.
An investigation by the ABC's 7.30 program has revealed that Dr Ralph Bright bought his liposuction-based technology from an American company.
The US company is now the subject of a multi-million dollar fraud action, which has revealed the cells being marketed as live were in fact dead.
Dr Bright, of Macquarie Stem Cells, is a former GP and self-taught cosmetic surgeon.
He has been working with stem cells for four years, treating more than 400 patients, including the late model Charlotte Dawson, cricketer Geoff Lawson and Olympic volleyballer Kerri Pottharst.
Dr Bright has licensed his methods to other practitioners around the country and because they use the patients' own cells he is not regulated by the Therapeutic Goods Administration (TGA).
Stem cells are often hailed as a miracle cure, but the nation's top stem cell scientists are warning that buyers should beware of these sorts of procedures, which are yet to be subjected to clinical trials.
Professor of Stem Cell Science at the University of Melbourne, Martin Pera, said almost all stem cell therapy was experimental.
"Actually, this whole science of cell therapy is relatively new and it's very, very important to understand that," he said.
See the original post:
Stem cell harvesting methods used by Sydney doctor Ralph Bright untested by clinical trials
ABC Ralph Bright harvests stem cells using the liposuction.
Serious questions have been raised about a stem cell doctor working in Western Sydney who charges $9,000 per procedure and uses methods that are untested by clinical trials.
An investigation by the ABC's 7.30 program has revealed that Dr Ralph Bright bought his liposuction-based technology from an American company.
The US company is now the subject of a multi-million dollar fraud action, which has revealed the cells being marketed as live were in fact dead.
Dr Bright, of Macquarie Stem Cells, is a former GP and self-taught cosmetic surgeon.
He has been working with stem cells for four years, treating more than 400 patients, including the late model Charlotte Dawson, cricketer Geoff Lawson and Olympic volleyballer Kerri Pottharst.
Dr Bright has licensed his methods to other practitioners around the country and because they use the patients' own cells he is not regulated by the Therapeutic Goods Administration (TGA).
Stem cells are often hailed as a miracle cure, but the nation's top stem cell scientists are warning that buyers should beware of these sorts of procedures, which are yet to be subjected to clinical trials.
Professor of Stem Cell Science at the University of Melbourne, Martin Pera, said almost all stem cell therapy was experimental.
"Actually, this whole science of cell therapy is relatively new and it's very, very important to understand that," he said.
Originally posted here:
Stem cells treatment used by Sydney doctor Ralph Bright 'untested' by clinical trials
If your beloved pets can no longer play fetch because they suffer from chronic hip or back pain, then you might be interested in a stem cell procedure. Its minimally invasive and its growing in popularity in Central Pennsylvania.
Ben, the Akita, is undergoing stem cell surgery to reverse his chronic arthritis in his hip.
Veterinarian, Dr. Roger Horst, of Mercersburg Animal Clinic says, It just makes it more comfortable for them to be a pet, normal activity without to be on pain drugs.
Through a 30 minute surgery, Dr. Horst removes fatty tissue from Bens shoulder. He hands over the tissue to a lab technician. The technician, Delaney Kennedy, works with MediVet, a global leader in veterinary science.
Kennedy says, When we filter this tissue, everything stops at the top of the filtration and stem cells collect at the bottom. The stem cells are what we want and thats what we inject back into Ben.
Within 30 days, Bens quality of life will improve without the need for medicine.
Kennedy says, As pet owners maybe before could have put him down because hes in pain but now, were able to use stem cell therapy and help him live longer.
For more information contact Mercersburg Animal Clinic or MediVet.
Original post:
JIJI PRESS/AFP/Getty Images
Masayo Takahashi is the first to implant tissue derived from induced pluripotent stem cells into a person.
Its awesome, its amazing, Im thrilled, Ive been waiting for this, says Jeanne Loring, a stem-cell biologist at the Scripps Research Institute in La Jolla, California. She is one of several researchers around the world to welcome the news that a Japanese woman with visual impairment had become the first person to receive a therapy derived from stem cells known as induced pluripotent stem (iPS) cells.
A lot rides on this trial. If the procedure proves safe, it could soften the stance of regulatory bodies in other nations towards human trials of iPS cells, and it could pave the way for treatments for other conditions, such as Parkinsons disease and diabetes. It could also cement Japan, recently plagued by a stem-cell scandal, as a frontrunner in iPS-cell research.
Pioneered in 2006 by Shinya Yamanaka, now director of the Center for iPS Cell Research and Applications at Kyoto University, iPS cells are created by inserting certain genes into the DNA of adult cells to reprogram the cells back to an embryonic-like state. The cells can then be turned into almost any tissue type, much as embryonic stem cells can. But because iPS cells can be derived from a patients own tissue, the hope is that they will dodge some of the controversial aspects and safety concerns of those derived from embryos.
In 2012, Yamanaka received a Nobel prize for his work, and the field has now matured, with teams across the world champing at the bit to test therapies based on iPS cells in people. Loring, for example, uses the cells to create dopamine-producing neurons as a potential therapy for Parkinsons disease, and says that she will start clinical trials as soon as the US Food and Drug Administration (FDA) gives the go-ahead.
Still, tissues made from iPS cells carry their own concerns, and that had stopped any country from approving them for a clinical trial. The bodys immune system could attack them, or they might contain some cells that are still in the pluripotent state and cause cancerous growths although Loring points out that this has not happened with human trials of therapies based on embryonic stem cells, for which the same concerns would apply.
In July 2013, however, Japans regulatory authorities gave the go-ahead for a team led by ophthalmologist Masayo Takahashi at the RIKEN Center for Developmental Biology (CDB) in Kobe to collect cells to be used in a clinical iPS-cell pilot study.
Her team took skin cells from the first patient, a woman in her seventies who had retinal damage owing to a condition known as age-related macular degeneration. The researchers then reprogrammed the skin cells into iPS cells and coaxed the unspecialized cells into becoming retinal tissue. On 8September, Takahashi provided evidence that those cells were genetically stable and safe, a prerequisite for them to be transplanted into the eye. The procedure took place four days later, and RIKEN has reported that the patient experienced no serious side effects.
In this instance, the womans vision is unlikely to improve. However, researchers around the world are watching to see whether the cells stop the retina from deteriorating further and whether any side effects develop. Should the woman experience serious consequences, iPS-cell research could be set back years, much as gene therapy was in 1999 when a patient died in a trial that attempted to use a modified gene to correct a type of liver disease. That wakes me up at night, Loring admits.
See more here:
Edgar Irastorza was just 31 when his heart stopped beating in October 2008.
A Miami property manager, break-dancer and former high school wrestler, Irastorza had recently gained weight as his wife's third pregnancy progressed. "I kind of got pregnant, too," he said.
During a workout one day, he felt short of breath and insisted that friends rush him to the hospital. Minutes later, his pulse flatlined.
He survived the heart attack, but the scar tissue that resulted cut his heart's pumping ability by a third. He couldn't pick up his children. He couldn't dance. He fell asleep every night wondering if he would wake up in the morning.
Desperation motivated Irastorza to volunteer for a highly unusual medical research trial: getting stem cells injected directly into his heart.
"I just trusted my doctors and the science behind it, and said, 'This is my only chance,'" he said recently.
Over the past five years, by studying stem cells in lab dishes, test animals and intrepid patients like Irastorza, researchers have brought the vague, grandiose promises of stem cell therapies closer to reality.
Stem cells broke into the public consciousness in the early 1990s, alluring for their potential to help the body beat back diseases of degeneration like Alzheimer's, and to grow new parts to treat conditions like spinal cord injuries.
Progress has been slow. The Michael J. Fox Foundation for Parkinson's Research, an early supporter of stem cell research, pulled its financial backing two years ago, saying that it preferred to invest in research that was closer to providing immediate help for Parkinson's disease patients.
But researchers have been slowly learning how to best use stem cells, what types to use and how to deliver them to the body - findings that are not singularly transformational, but progressive and pragmatic.
See more here:
4 hours ago Stem cells. Credit: Nissim Benvenisty - Wikipedia
Researchers at the Hebrew University of Jerusalem have developed a new cocktail that is highly effective at coaxing adult cells to become quality pluripotent stem cells.
Regenerative medicine is a new and expanding area that aims to replace lost or damaged cells, tissues or organs through cellular transplantation. Because stem cells derived from human embryos can trigger ethical concerns, a good solution is reprogramming adult cells back to an embryo-like state using a combination of reprogramming factors.
The resulting cells, called induced pluripotent stem cells (iPSCs), could be used to replace those lost to damage or disease. However, scientists have discovered that the process of reprogramming adult cells can introduce genetic abnormalities that limit the cells' usefulness in research and medicine.
To make iPSCs, scientists expose adult cells to a cocktail of genes that are active in embryonic stem cells. iPSCs can then be coaxed to differentiate into other cell types such as nerve or muscle. However, the standard combination of factors used to reprogram cells leads to a high percentage of serious genomic aberrations in the resulting cells. (The reprogramming factors are Oct4, Sox2, Klf4, and Mycknown collectively as OSKM).
Now researchers at the Hebrew University of Jerusalem have developed a new cocktail of reprogramming factors that produce high-quality iPSCs. Dr. Yosef Buganim, at the Institute for Medical Research Israel-Canada in the Hebrew University's Faculty of Medicine, worked with scientists at the lab of Whitehead Institute founding member Rudolf Jaenisch, a professor of biology at MIT.
The researchers reasoned that changing the reprogramming factors could reprogram the adult cells in a more controlled way and yield high-quality iPSCs. Working with mouse cells, Dr. Buganim and research scientist Styliani Markoulaki used bioinformatic analysis to design a new cocktail of reprogramming factors (Sall4, Nanog, Esrrb, and Lin28, known collectively as SNEL).
Their results showed that the interaction between reprogramming factors plays a crucial role in determining the quantity and quality of resulting iPSCsand that a different combination of reprogramming factors can in fact produce a much higher quality product.
The new SNEL cocktail created fewer colonies of iPSCs, but approximately 80% of those produced passed the most stringent pluripotency test. This is highly preferable to the traditional OSKM cocktail, which produces a large number of colonies but the majority of which fail the pluripotency test.
Dr. Buganim hypothesizes that SNEL may reprogram cells better than OSKM because it does not rely on the master regulators Oct4 and Sox2, which might activate part of the adult cell genome. According to Buganim, the research demonstrates the effectiveness of bioinformatics tools in producing high quality iPSCs.
See more here:
Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells
Laminine Testimonials stroke
Laminine is availabe in the Philippines!!! "The Closest Alternative To Stem Cell Therapy..." "The miracle formula from a 9-day-old fertilized hen eggs" For More Info About Laminine, How a...
By: Karl Angelo Alipin
The rest is here:
Laminine Testimonial-kidney failure
Laminine is availabe in the Philippines!!! "The Closest Alternative To Stem Cell Therapy..." "The miracle formula from a 9-day-old fertilized hen eggs" For More Info About Laminine, How a...
By: Karl Angelo Alipin
See the article here:
Albany, NY (PRWEB) September 15, 2014
Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc..
View Full Report at http://www.marketresearchreports.biz/analysis/223134
Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.
Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/223134
The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.
Browse All Published Reports by Same Publisher at http://www.marketresearchreports.biz/publisher/67
Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOSTs adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD).
In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter.
Related Reports
The rest is here:
Stem Cell Therapy for Osteoarthritis
Ross Hauser, MD explains Stem Cell Prolotherapy using whole bone marrow. If you have osteoarthritis and are interested in how stem cell therapy may help you, we would love to see you in one...
By: Caring Medical and Rehabilitation Services
Read this article:
Spinal cord injury - Case Study- Stem cell therapy- Giostar
a brief introduction to Giostar and its Stem cell therapy Dr.Divyang Patel (MD) a spine surgeon at Giostar- INDIA, briefs about a case of cervical spine injury, which is also examined by a...
By: Devang Parmar
Go here to read the rest:
Spinal cord injury - Case Study- Stem cell therapy- Giostar - Video
GIOSTAR- STEM CELL THERAPY DR ANAND SHRIVASTAVA
Global Institute of Stem cell Therapy and Research - GIOSTAR Introduction to Stem Cell Therapy, and Dr.Anand Shrivastava - Chairman Co-founder of GIOSTAR.
By: Devang Parmar
Read more here: